SSTR1 and prostate carcinoma: In the 115 Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF) West Coast Dream Team (WCDT) patients (retrospectively ascertained) with both survival and RNA-Seq data available, we found that lower SSTR1 mRNA expression was associated with reduced benefit from ARSIs following biopsy (interaction P = 0.0598, Figure 5D) and worse overall survival (Supplemental Figure 22A).